Clinical data | |
---|---|
Routes of administration | oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
E number | E710 (antibiotics) |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.029.476 |
Chemical and physical data | |
Formula | C43H74N2O14 |
Molar mass | 843.065 g·mol−1 |
3D model (JSmol) | |
Melting point | 134 to 137 °C (273 to 279 °F) |
Solubility in water | Insoluble in water; Very soluble in acetonitrile and methanol; Almost completely(>99.5) in ethanol. mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Spiramycin is a macrolide antibiotic and antiparasitic. It is used to treat toxoplasmosis and various other infections of soft tissues.
Although used in Europe, Canada and Mexico,[1] spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy.[2] Spiramycin has been used in Europe since the year 2000 under the trade name "Rovamycine", produced by Rhone-Poulenc Rorer, Sanofi and Famar Lyon, France and Eczacıbaşı İlaç, Turkey. It also goes under the name Rovamycine in Canada (distributed by OdanLaboratories), where it is mostly marketed to dentists for mouth infections.[citation needed] Spiramycin has been studied as a virulence inhibitor in Pseudomonas aeruginosa.[3]
MayoClinic_Toxoplasmosis
was invoked but never defined (see the help page).